Including a Mainland China approach within the market plan can extend the revenue-generating life of these drugs beyond the expected patent expiry in the United States and Europe.
Of the nine selected, eight are oncology drugs, which is likely driven by healthcare reforms under Healthy China 2030 that have placed a focus on addressing the increasing cancer burden in Mainland China. It was estimated that 4.8 million new cancer cases and 3.2 million cancer-related deaths would occur in Mainland China in 2022.
|Drug||Company(s)||U.S. approval||European Approval||Mainland China approval||2021 Sales in Mainland China ($M)||Expected patent expiry in Mainland China|
|Anlotinib (Focus V®)||Chia Tai Tianqing Pharmaceutical (CTTQ)||N/A||N/A||2018||620||2028|
|Camrelizumab (AiRuiKa™)||Jiangsu Hengrui Medicine Co Ltd||N/A||N/A||2019||600||2036|
|Nivolumab (OPDIVO®)||Bristol Myers Squibb||2014||2015||2018||7,523||2026|
|Sintilimab (TYVYT®)||Innovent Biologics Inc and Eli Lilly and Company||N/A||2020||2018||418||2036|
|Trastuzumab (HERCEPTIN®)||Roche||1998||2000||2002||2,700||Biosimilars available|